Akuru Pharma Overview
- Year Founded
-
2016
- Status
-
Out of Business
- Employees
-
3
- Latest Deal Type
-
Out of Business
Akuru Pharma General Information
Description
Developer of a bioinformatics platform designed to develop novel diagnostic and treatment modalities. The company's platform is used for the identification of novel surface molecules that can serve as biomarkers for kidney cancer, with a particular focus on transporter proteins, and can be utilized for both diagnostic and therapeutic purposes, thereby enabling doctors to develop novel diagnostic and treatment modalities and find an effective treatment for kidney cancer.
Contact Information
Website
www.akurupharma.comCorporate Office
- Lilla Algatan 9B
- 223 50 Lund
- Sweden
Corporate Office
- Lilla Algatan 9B
- 223 50 Lund
- Sweden
Akuru Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Out of Business | 03-Nov-2020 | Completed | Out of Business | |||
| 5. Grant | 27-Oct-2017 | Completed | Generating Revenue | |||
| 4. Accelerator/Incubator | 01-Jun-2017 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 15-Nov-2016 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 11-Jun-2016 | Completed | Generating Revenue | |||
| 1. University Spin-Out | 01-Jan-2016 | Completed | Startup |
Akuru Pharma Patents
Akuru Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2016294377-A1 | Detection and treatment of renal cell carcinoma with a slc6a3 ligand linked to a label, cytotoxic or immunomodulatory group | Inactive | 16-Jul-2015 | ||
| CA-2989507-A1 | Detection and treatment of renal cell carcinoma with a slc6a3 ligand linked to a label, cytotoxic or immunomodulatory group | Inactive | 16-Jul-2015 | ||
| EP-3322450-A1 | Detection and treatment of renal cell carcinoma with a slc6a3 ligand linked to a label, cytotoxic or immunomodulatory group | Inactive | 16-Jul-2015 | ||
| US-20180200392-A1 | Detection and treatment of renal cell carcinoma with a slc6a3 ligand linked to a label, cytotoxic or immunomodulatory group | Inactive | 16-Jul-2015 | ||
| WO-2017009084-A1 | Detection and treatment of renal cell carcinoma with a slc6a3 ligand linked to a label, cytotoxic or immunomodulatory group | Inactive | 16-Jul-2015 | A61K51/0448 |
Akuru Pharma Signals
Akuru Pharma FAQs
-
When was Akuru Pharma founded?
Akuru Pharma was founded in 2016.
-
Where is Akuru Pharma headquartered?
Akuru Pharma is headquartered in Lund, Sweden.
-
What is the size of Akuru Pharma?
Akuru Pharma has 3 total employees.
-
What industry is Akuru Pharma in?
Akuru Pharma’s primary industry is Drug Discovery.
-
Is Akuru Pharma a private or public company?
Akuru Pharma is a Private company.
-
What is Akuru Pharma’s current revenue?
The current revenue for Akuru Pharma is .
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process